Internationally recognized stem cell researcher joins Chemokine's Scientific and Clinical Advisory Boards
Chemokine Therapeutics Corp. announced that Dr. Shahin Rafii, a stem cell researcher from Cornell University Medical College, New York, has joined the Company's Scientific and Clinical Advisory boards. Comprised of leading oncologists and scientists, Chemokine's advisory boards play an important role in guiding and participating in Chemokine's research and clinical development programs.
Dr. Rafii is the Arthur B. Belfer Professor of Genetic Medicine at Weill-Cornell Medical College. Dr. Rafii, who is a board certified Hematologist-Oncologist, is engaged in patient care, and basic and translational research. He has expertise in basic tumor biology as well as vascular and stem cell biology. He was recently appointed to spearhead the Ansary Stem Cell Center for Regenerative Medicine at Weill-Cornell. Dr. Rafii was recently elected to Howard Hughes Medical Institute.
Dr. Rafii graduated from Cornell University in 1982, with a degree of Cum Laude in Chemistry and was awarded Phi Beta Kappa. He received his MD degree from Albert Einstein College of Medicine with Honors and was elected to AOA society in 1986. Subsequently, in 1989, he completed his internship and residency in Internal Medicine followed by a fellowship in Hematology-Oncology at Weill-Cornell in 1992. By 1996, he completed his post-doctoral training in vascular and hematopoietic stem cell biology under supervision of Dr. Ralph Nachman at Weill-Cornell. He became a full professor in Genetic Medicine in 2002, at which time he was appointed to be the co-director of the Ansary Stem Cell Research Center in New York.
Other news from the department people
